WeVote
Log In

Bill

Bill

SB 221

AN ACT RELATING TO INSURANCE -- THIRD-PARTY HEALTH INSURANCE ADMINISTRATORS -- PRESCRIPTION DRUG COST CONTROL AND TRANSPARENCY

2025 Regular Session Introduced by Jonathon Acosta and 9 co-sponsors

SB 221 requires third-party prescription drug administrators to disclose pricing practices and implement cost controls, increasing transparency but potentially raising administrative costs and facing industry resistance.

03/20/2025 Committee recommended measure be held for further study
0
WeVote Research Nonpartisan
Bill Summary · SB 221

Legislative bill overview

SB 221 establishes new regulatory requirements for third-party health insurance administrators (TPAs) managing prescription drug benefits, focusing on cost control and transparency measures. The bill aims to increase visibility into drug pricing practices and potentially reduce out-of-pocket costs for Rhode Island residents by imposing disclosure and operational standards on entities that process pharmacy claims.

Why is this important

Prescription drug costs represent a significant portion of healthcare spending, and TPAs operate with limited public oversight despite controlling access and pricing for millions of insured individuals. Rhode Island residents and employers have limited insight into how TPAs negotiate drug prices, set formularies, and structure pharmacy networks—transparency could reveal whether competitive practices are being undermined and inform future cost containment strategies.

Potential points of contention

  • Industry pushback: TPAs may argue that mandatory disclosures of negotiation strategies, rebate agreements, and pricing formulas constitute proprietary business information that competitive entities shouldn't access
  • Implementation costs: New compliance requirements could increase administrative costs for TPAs, potentially passed to insurers and ultimately consumers through higher premiums
  • Scope ambiguity: The bill's specific requirements aren't detailed in available information; overly broad mandates risk unintended consequences, while narrow ones may fail to achieve meaningful transparency

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.